ArticleDiscover oncology2025
RAD51-AS1 inhibits the migration and invasion of prostate cancer cells by up-regulating RARA to activate ZYX transcription.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- LncRNA RAD51-AS1 Alleviates Oxidative Stress and Inflammation in Diabetic Nephropathy by Adsorbing miR-154-5p.Kidney & blood pressure research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundProstate cancer (PCa) is one of the most prevailing cancers threatening men health around the world. Mounting studies have revealed that dysregulated long non-coding RNAs (lncRNAs) might contribute to cancer development. RAD51-AS1 has been reported as an tumor-suppressor in different diseases, but not in PCa. Therefore, we aimed to explore the role of RAD51-AS1 and the underlying regulatory mechanism in PCa.
methodsRT-qPCR was conducted for the measurement of RNA levels. Bioinformatics analysis was performed for screening out possible research targets. Mechanism assays were implemented for detecting relations among different factors, while functional assays were employed to determine the function of genes in PCa cells.
resultRAD51-AS1 expression was found to be low in PCa cells, which resulted in exacerbated PCa cell migration and invasion. RAD51-AS1 recruited HNRNPC in PCa cell nucleus to bind with pre-RARA, thus positively modulating RARA expression. RARA activated ZYX transcription to enhance ZYX expression in PCa cells. Rescue assay substantiated RAD51-AS1 inhibited PCa cell migration and invasion through modulating ZYX expression.
conclusionThe anti-oncogenic role of RAD51-AS1 was realized through HNRNPC/RARA/ZYX axis, which might offer a novel insight for understanding PCa.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.